Loading...

Joseph Tuscano

Title(s)Professor, Hematology and Oncology
SchoolUniversity of California, Davis
Phone916-734-3772
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Tuscano JM, Maverakis E, Groshen S, Tsao-Wei D, Luxardi G, Merleev AA, Beaven A, DiPersio JF, Popplewell L, Chen R, Kirschbaum M, Schroeder MA, Newman EM. A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma. Clin Cancer Res. 2019 Sep 03. PMID: 31481504.
      View in: PubMed
    2. Tomlinson BK, Tuscano JM, Abedi M, Welborn J, Arora M, O'Donnell RT, Wun T, Jonas BA. A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia. Am J Hematol. 2019 Nov; 94(11):E291-E294. PMID: 31379016.
      View in: PubMed
    3. Takebe N, Beumer JH, Kummar S, Kiesel BF, Dowlati A, O'Sullivan Coyne G, Piekarz R, Rubinstein L, Fogli LK, Vaishampayan U, Goel S, O'Bryant CL, El-Rayes BF, Chung V, Lenz HJ, Kim R, Belani CP, Tuscano JM, Schelman W, Moore N, Doroshow JH, Chen AP. A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. Br J Clin Pharmacol. 2019 Jul 04. PMID: 31271459.
      View in: PubMed
    4. Vogel CFA, Ishihara Y, Campbell CE, Kado SY, Nguyen-Chi A, Sweeney C, Pollet M, Haarmann-Stemmann T, Tuscano JM. A Protective Role of Aryl Hydrocarbon Receptor Repressor in Inflammation and Tumor Growth. Cancers (Basel). 2019 Apr 27; 11(5). PMID: 31035533.
      View in: PubMed
    5. McHardy I, Romanelli A, Harris LJ, Opp G, Gaudino R, Torres A, Polage CR, Tuscano JM, Thompson GR. Infectious risks associated with medicinal Cannabis: Potential implications for immunocompromised patients? J Infect. 2018 05; 76(5):500-501. PMID: 29408325.
      View in: PubMed
    6. Barisone GA, O'Donnell RT, Ma Y, Abuhay MW, Lundeberg K, Gowda S, Tuscano JM. A purified, fermented, extract of Triticum aestivum has lymphomacidal activity mediated via natural killer cell activation. PLoS One. 2018; 13(1):e0190860. PMID: 29304125.
      View in: PubMed
    7. Rosenberg AS, Brunson A, Paulus JK, Tuscano J, Wun T, Keegan THM, Jonas BA. Secondary acute lymphoblastic leukemia is a distinct clinical entity with prognostic significance. Blood Cancer J. 2017 09 08; 7(9):e605. PMID: 28885611.
      View in: PubMed
    8. Witzig TE, Luigi Zinzani P, Habermann TM, Tuscano JM, Drach J, Ramchandren R, Kalayoglu Besisik S, Takeshita K, Casadebaig Bravo ML, Zhang L, Fu T, Goy A. Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma. Am J Hematol. 2017 Oct; 92(10):E575-E583. PMID: 28699256.
      View in: PubMed
    9. Thompson GR, Tuscano JM, Dennis M, Singapuri A, Libertini S, Gaudino R, Torres A, Delisle JM, Gillece JD, Schupp JM, Engelthaler DM. A microbiome assessment of medical marijuana. Clin Microbiol Infect. 2017 04; 23(4):269-270. PMID: 27956269.
      View in: PubMed
    10. Yoshida S, Tuscano E, Duong C, Chung J, Li Y, Beckett L, Tuscano JM, Satake N. Efficacy of an anti-CD22 antibody-monomethyl auristatin E conjugate in a preclinical xenograft model of precursor B-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2017 05; 58(5):1254-1257. PMID: 27701909.
      View in: PubMed
    11. Kirschbaum MH, Frankel P, Synold TW, Zain J, Claxton D, Tuscano J, Newman EM, Gandara DR, Lara PN. A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study. Br J Haematol. 2018 02; 180(3):445-448. PMID: 27650362.
      View in: PubMed
    12. Abuhay M, Kato J, Tuscano E, Barisone GA, Sidhu RS, O'Donnell RT, Tuscano JM. The HB22.7-vcMMAE antibody-drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity. Cancer Immunol Immunother. 2016 10; 65(10):1169-75. PMID: 27506529.
      View in: PubMed
    13. Petukhova TA, Tartar DM, Mayo K, Fung MA, Tuscano J, Jagdeo J. Erythema Nodosum-like Septal Panniculitis Secondary to Lenalidomide Therapy in a Patient With Janus Kinase 2-Positive Myelofibrosis. J Drugs Dermatol. 2016 Aug 01; 15(8):1024-5. PMID: 27538006.
      View in: PubMed
    14. Arora M, Gowda S, Tuscano J. A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma. Ther Adv Hematol. 2016 Aug; 7(4):209-21. PMID: 27493711.
      View in: PubMed
    15. Kirschbaum MH, Frankel P, Synold TW, Xie Z, Yen Y, Popplewell L, Chen R, Aljitawi O, Tuscano JM, Chan KK, Newman EM. A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study. Leuk Lymphoma. 2016 10; 57(10):2307-14. PMID: 26895565.
      View in: PubMed
    16. Diefenbach CS, Li H, Hong F, Gordon LI, Fisher RI, Bartlett NL, Crump M, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Stewart DA, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ, Advani RH. Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. Br J Haematol. 2015 Nov; 171(4):530-8. PMID: 26343802.
      View in: PubMed
    17. Kong Y, Barisone GA, Sidhu RS, O'Donnell RT, Tuscano JM. Efficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma. Mol Med. 2015 Nov; 21(1):824-832. PMID: 26322845.
      View in: PubMed
    18. Advani RH, Hong F, Fisher RI, Bartlett NL, Robinson KS, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Stewart DA, Gordon LI, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. J Clin Oncol. 2015 Jun 10; 33(17):1936-42. PMID: 25897153.
      View in: PubMed
    19. Satake N, Duong C, Chen C, Barisone GA, Diaz E, Tuscano J, Rocke DM, Nolta J, Nitin N. Targeted therapy with MXD3 siRNA, anti-CD22 antibody and nanoparticles for precursor B-cell acute lymphoblastic leukaemia. Br J Haematol. 2014 Nov; 167(4):487-99. PMID: 25196579.
      View in: PubMed
    20. Kong Y, Barisone GA, Abuhay M, O'Donnell RT, Buksh Z, Yousefian F, Tuscano JM. Histone deacetylase inhibition enhances the lymphomacidal activity of the anti-CD22 monoclonal antibody HB22.7. Leuk Res. 2014 Nov; 38(11):1320-6. PMID: 25241275.
      View in: PubMed
    21. Thompson GR, Tuscano JM. Adverse health effects of marijuana use. N Engl J Med. 2014 08 28; 371(9):878-9. PMID: 25162901.
      View in: PubMed
    22. Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, Shannon M, Flinn IW, Byrd JC. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. Br J Haematol. 2014 Nov; 167(4):466-77. PMID: 25130401.
      View in: PubMed
    23. Tuscano JM, Dutia M, Chee K, Brunson A, Reed-Pease C, Abedi M, Welborn J, O'Donnell RT. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma. Br J Haematol. 2014 May; 165(3):375-81. PMID: 24606326.
      View in: PubMed
    24. Wang M, Popplewell LL, Collins RH, Winter JN, Goy A, Kaminski MS, Bartlett NL, Johnston PB, Lister J, Fanning SR, Tuscano JM, Beck JT, Kaya H, Robeva A, Fan J, Klimovsky J, Cheung W, Cherfi A, O'Connor OA. Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study. Br J Haematol. 2014 May; 165(4):510-8. PMID: 24579926.
      View in: PubMed
    25. Kirschbaum MH, Foon KA, Frankel P, Ruel C, Pulone B, Tuscano JM, Newman EM. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leuk Lymphoma. 2014 Oct; 55(10):2301-4. PMID: 24369094.
      View in: PubMed
    26. Bass GF, Tuscano ET, Tuscano JM. Diagnosis and classification of autoimmune hemolytic anemia. Autoimmun Rev. 2014 Apr-May; 13(4-5):560-4. PMID: 24418298.
      View in: PubMed
    27. Sullivan-Chang L, O'Donnell RT, Tuscano JM. Targeting CD22 in B-cell malignancies: current status and clinical outlook. BioDrugs. 2013 Aug; 27(4):293-304. PMID: 23696252.
      View in: PubMed
    28. Vose JM, Habermann TM, Czuczman MS, Zinzani PL, Reeder CB, Tuscano JM, Lossos IS, Li J, Pietronigro D, Witzig TE. Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation. Br J Haematol. 2013 Sep; 162(5):639-47. PMID: 23834234.
      View in: PubMed
    29. Kato J, O'Donnell RT, Abuhay M, Tuscano JM. Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphoma. Oncoimmunology. 2012 Dec 01; 1(9):1469-1475. PMID: 23264893.
      View in: PubMed
    30. Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Gospodarowicz M, Advani R, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013 Feb 20; 31(6):684-91. PMID: 23182987.
      View in: PubMed
    31. Kato J, Satake N, O'Donnell RT, Abuhay M, Lewis C, Tuscano JM. Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia. Leuk Res. 2013 Jan; 37(1):83-8. PMID: 23040543.
      View in: PubMed
    32. Tuscano JM, Kato J, Pearson D, Xiong C, Newell L, Ma Y, Gandara DR, O'Donnell RT. CD22 antigen is broadly expressed on lung cancer cells and is a target for antibody-based therapy. Cancer Res. 2012 Nov 01; 72(21):5556-65. PMID: 22986740.
      View in: PubMed
    33. Kato J, Li Y, Xiao K, Lee JS, Luo J, Tuscano JM, O'Donnell RT, Lam KS. Disulfide cross-linked micelles for the targeted delivery of vincristine to B-cell lymphoma. Mol Pharm. 2012 Jun 04; 9(6):1727-35. PMID: 22530955.
      View in: PubMed
    34. Martin SM, Churchill E, McKnight H, Mahaffey CM, Ma Y, O'Donnell RT, Tuscano JM. The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner. J Hematol Oncol. 2011 Dec 01; 4:49. PMID: 22128838.
      View in: PubMed
    35. Kirschbaum MH, Synold T, Stein AS, Tuscano J, Zain JM, Popplewell L, Karanes C, O'Donnell MR, Pulone B, Rincon A, Wright J, Frankel P, Forman SJ, Newman EM. A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia. Leukemia. 2011 Oct; 25(10):1543-7. PMID: 21625235.
      View in: PubMed
    36. Somlo G, Lashkari A, Bellamy W, Zimmerman TM, Tuscano JM, O'Donnell MR, Mohrbacher AF, Forman SJ, Frankel P, Chen HX, Doroshow JH, Gandara DR. Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial. Br J Haematol. 2011 Aug; 154(4):533-5. PMID: 21517811.
      View in: PubMed
    37. Tuscano JM, Ma Y, Martin SM, Kato J, O'Donnell RT. The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone. Cancer Immunol Immunother. 2011 Jun; 60(6):771-80. PMID: 21347809.
      View in: PubMed
    38. Tuscano JM, Martin SM, Ma Y, Zamboni W, O'Donnell RT. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model. Clin Cancer Res. 2010 May 15; 16(10):2760-8. PMID: 20460479.
      View in: PubMed
    39. Moritoki Y, Lian ZX, Lindor K, Tuscano J, Tsuneyama K, Zhang W, Ueno Y, Dunn R, Kehry M, Coppel RL, Mackay IR, Gershwin ME. B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice. Hepatology. 2009 Dec; 50(6):1893-903. PMID: 19877182.
      View in: PubMed
    40. Sands J, Tuscano JM. Geoepidemiology and autoimmune manifestations of lymphoproliferative disorders. Autoimmun Rev. 2010 Mar; 9(5):A335-41. PMID: 19914405.
      View in: PubMed
    41. Tuscano JM, Sands J. B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis. Biologics. 2009; 3:225-32. PMID: 19707411.
      View in: PubMed
    42. O'Donnell RT, Ma Y, McKnight HC, Pearson D, Tuscano JM. Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts. Cancer Immunol Immunother. 2009 Dec; 58(12):2051-8. PMID: 19437017.
      View in: PubMed
    43. Khan IH, Krishnan VV, Ziman M, Janatpour K, Wun T, Luciw PA, Tuscano J. A comparison of multiplex suspension array large-panel kits for profiling cytokines and chemokines in rheumatoid arthritis patients. Cytometry B Clin Cytom. 2009 May; 76(3):159-68. PMID: 18823005.
      View in: PubMed
    44. O'Donnell RT, Martin SM, Ma Y, Zamboni WC, Tuscano JM. Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD). Invest New Drugs. 2010 Jun; 28(3):260-7. PMID: 19306119.
      View in: PubMed
    45. O'Donnell RT, Pearson D, McKnight HC, Ma YP, Tuscano JM. Treatment of non-Hodgkin's lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy. Cancer Immunol Immunother. 2009 Oct; 58(10):1715-22. PMID: 19294384.
      View in: PubMed
    46. Habermann TM, Lossos IS, Justice G, Vose JM, Wiernik PH, McBride K, Wride K, Ervin-Haynes A, Takeshita K, Pietronigro D, Zeldis JB, Tuscano JM. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol. 2009 May; 145(3):344-9. PMID: 19245430.
      View in: PubMed
    47. O'Donnell RT, Pearson D, McKnight HC, Ma YP, Tuscano JM. Phosphatase inhibition augments anti-CD22-mediated signaling and cytotoxicity in non-hodgkin's lymphoma cells. Leuk Res. 2009 Jul; 33(7):964-9. PMID: 19237192.
      View in: PubMed
    48. Martin SM, O'Donnell RT, Kukis DL, Abbey CK, McKnight H, Sutcliffe JL, Tuscano JM. Imaging and pharmacokinetics of (64)Cu-DOTA-HB22.7 administered by intravenous, intraperitoneal, or subcutaneous injection to mice bearing non-Hodgkin's lymphoma xenografts. Mol Imaging Biol. 2009 Mar-Apr; 11(2):79-87. PMID: 18949521.
      View in: PubMed
    49. Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Habermann TM. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2008 Oct 20; 26(30):4952-7. PMID: 18606983.
      View in: PubMed
    50. Tuscano JM. Multiple myeloma: epidemiology and therapeutic options. Manag Care. 2008 Jul; 17(7 Suppl 6):9-15. PMID: 19093334.
      View in: PubMed
    51. Chan JW, Taylor DS, Lane SM, Zwerdling T, Tuscano J, Huser T. Nondestructive identification of individual leukemia cells by laser trapping Raman spectroscopy. Anal Chem. 2008 Mar 15; 80(6):2180-7. PMID: 18260656.
      View in: PubMed
    52. Vogel CF, Li W, Sciullo E, Newman J, Hammock B, Reader JR, Tuscano J, Matsumura F. Pathogenesis of aryl hydrocarbon receptor-mediated development of lymphoma is associated with increased cyclooxygenase-2 expression. Am J Pathol. 2007 Nov; 171(5):1538-48. PMID: 17823287.
      View in: PubMed
    53. Khan IH, Mendoza S, Rhyne P, Ziman M, Tuscano J, Eisinger D, Kung HJ, Luciw PA. Multiplex analysis of intracellular signaling pathways in lymphoid cells by microbead suspension arrays. Mol Cell Proteomics. 2006 Apr; 5(4):758-68. PMID: 16369048.
      View in: PubMed
    54. Tuscano JM, Martin S, Song K, Wun T. B cell reductive therapy in the treatment of autoimmune diseases: a focus on monoclonal antibody treatment of rheumatoid arthritis. Hematology. 2005 Dec; 10(6):521-7. PMID: 16321818.
      View in: PubMed
    55. Higashida J, Wun T, Schmidt S, Naguwa SM, Tuscano JM. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment. J Rheumatol. 2005 Nov; 32(11):2109-15. PMID: 16265687.
      View in: PubMed
    56. Richman CM, Denardo SJ, O'Donnell RT, Yuan A, Shen S, Goldstein DS, Tuscano JM, Wun T, Chew HK, Lara PN, Kukis DL, Natarajan A, Meares CF, Lamborn KR, DeNardo GL. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clin Cancer Res. 2005 Aug 15; 11(16):5920-7. PMID: 16115934.
      View in: PubMed
    57. Martel CL, Li Y, Beckett L, Chew H, Christensen S, Davies A, Lam KS, Lau DH, Meyers FJ, O'donnell RT, Richman C, Scudder S, Tanaka M, Tuscano J, Welborn J, Wun T, Gandara DR, Lara PN. An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California. Cancer J. 2004 Sep-Oct; 10(5):294-300. PMID: 15530258.
      View in: PubMed
    58. Wun T, McKnight H, Tuscano JM. Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma. Leuk Res. 2004 Feb; 28(2):179-90. PMID: 14654083.
      View in: PubMed
    59. Lam KS, Liu R, Miyamoto S, Lehman AL, Tuscano JM. Applications of one-bead one-compound combinatorial libraries and chemical microarrays in signal transduction research. Acc Chem Res. 2003 Jun; 36(6):370-7. PMID: 12809522.
      View in: PubMed
    60. Tuscano JM, Harris GS, Tedder TF. B lymphocytes contribute to autoimmune disease pathogenesis: current trends and clinical implications. Autoimmun Rev. 2003 Mar; 2(2):101-8. PMID: 12848966.
      View in: PubMed
    61. Tuscano JM, O'Donnell RT, Miers LA, Kroger LA, Kukis DL, Lamborn KR, Tedder TF, DeNardo GL. Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts. Blood. 2003 May 01; 101(9):3641-7. PMID: 12511412.
      View in: PubMed
    62. Hutchinson K, Kopko PM, Muto KN, Tuscano J, O'Donnell RT, Holland PV, Richman C, Paglieroni TG, Wun T. Early diagnosis and successful treatment of a patient with transfusion-associated GVHD with autologous peripheral blood progenitor cell transplantation. Transfusion. 2002 Dec; 42(12):1567-72. PMID: 12473136.
      View in: PubMed
    63. Tuscano JM, Hsu TC, McKnight H, Ansari AA, Gershwin ME. Phosphorylation abnormalities: NZB mice exhibit a B-cell signalling defect. J Autoimmun. 2002 Nov; 19(3):103-9. PMID: 12419280.
      View in: PubMed
    64. Law L, Tuscano J, Wun T, Ahlberg K, Richman C. Filgrastim treatment of acute myelogenous leukemia (M7) relapse after allogeneic peripheral stem cell transplantation resulting in both graft-versus-leukemia effect with cytogenetic remission and chronic graft-versus-host disease manifesting as polyserositis and subsequent bronchiolitis obliterans with organizing pneumonia. Int J Hematol. 2002 Nov; 76(4):360-4. PMID: 12463601.
      View in: PubMed
    65. Wang SE, Lara PN, Lee-Ow A, Reed J, Wang LR, Palmer P, Tuscano JM, Richman CM, Beckett L, Wun T. Acetaminophen and diphenhydramine as premedication for platelet transfusions: a prospective randomized double-blind placebo-controlled trial. Am J Hematol. 2002 Jul; 70(3):191-4. PMID: 12111764.
      View in: PubMed
    66. Martel L, Reddy K, Greco M, Tuscano M, Richman M, Wun T. Isolated cavernous sinus extramedullary relapse of chronic myelogenous leukemia following allogeneic stem cell transplant. Ann Hematol. 2002 Feb; 81(2):108-10. PMID: 11907793.
      View in: PubMed
    67. Dhodapkar MV, Jacobson JL, Gertz MA, Rivkin SE, Roodman GD, Tuscano JM, Shurafa M, Kyle RA, Crowley JJ, Barlogie B. Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood. 2001 Jul 01; 98(1):41-8. PMID: 11418461.
      View in: PubMed
    68. Lara PN, Higdon R, Lim N, Kwan K, Tanaka M, Lau DH, Wun T, Welborn J, Meyers FJ, Christensen S, O'Donnell R, Richman C, Scudder SA, Tuscano J, Gandara DR, Lam KS. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol. 2001 Mar 15; 19(6):1728-33. PMID: 11251003.
      View in: PubMed
    69. Wun T, Kwon DS, Tuscano JM. Radioimmunotherapy: potential as a therapeutic strategy in non-Hodgkin's lymphoma. BioDrugs. 2001; 15(3):151-62. PMID: 11437681.
      View in: PubMed
    70. Shi CS, Tuscano J, Kehrl JH. Adaptor proteins CRK and CRKL associate with the serine/threonine protein kinase GCKR promoting GCKR and SAPK activation. Blood. 2000 Feb 01; 95(3):776-82. PMID: 10648385.
      View in: PubMed
    71. Tuscano JM, Riva A, Toscano SN, Tedder TF, Kehrl JH. CD22 cross-linking generates B-cell antigen receptor-independent signals that activate the JNK/SAPK signaling cascade. Blood. 1999 Aug 15; 94(4):1382-92. PMID: 10438726.
      View in: PubMed
    72. Shi CS, Tuscano JM, Witte ON, Kehrl JH. GCKR links the Bcr-Abl oncogene and Ras to the stress-activated protein kinase pathway. Blood. 1999 Feb 15; 93(4):1338-45. PMID: 9949177.
      View in: PubMed
    73. Sato S, Tuscano JM, Inaoki M, Tedder TF. CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor. Semin Immunol. 1998 Aug; 10(4):287-97. PMID: 9695185.
      View in: PubMed
    74. Tedder TF, Tuscano J, Sato S, Kehrl JH. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol. 1997; 15:481-504. PMID: 9143697.
      View in: PubMed
    75. Rieckmann P, Tuscano JM, Kehrl JH. Tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in B-lymphocyte function. Methods. 1997 Jan; 11(1):128-32. PMID: 8990098.
      View in: PubMed
    76. Tuscano JM, Druey KM, Riva A, Pena J, Thompson CB, Kehrl JH. Bcl-x rather than Bcl-2 mediates CD40-dependent centrocyte survival in the germinal center. Blood. 1996 Aug 15; 88(4):1359-64. PMID: 8695854.
      View in: PubMed
    77. Tuscano J, Engel P, Tedder TF, Kehrl JH. Engagement of the adhesion receptor CD22 triggers a potent stimulatory signal for B cells and blocking CD22/CD22L interactions impairs T-cell proliferation. Blood. 1996 Jun 01; 87(11):4723-30. PMID: 8639842.
      View in: PubMed
    78. Tuscano JM, Engel P, Tedder TF, Agarwal A, Kehrl JH. Involvement of p72syk kinase, p53/56lyn kinase and phosphatidyl inositol-3 kinase in signal transduction via the human B lymphocyte antigen CD22. Eur J Immunol. 1996 Jun; 26(6):1246-52. PMID: 8647200.
      View in: PubMed
    79. Tortolani PJ, Lal BK, Riva A, Johnston JA, Chen YQ, Reaman GH, Beckwith M, Longo D, Ortaldo JR, Bhatia K, McGrath I, Kehrl J, Tuscano J, McVicar DW, O'Shea JJ. Regulation of JAK3 expression and activation in human B cells and B cell malignancies. J Immunol. 1995 Dec 01; 155(11):5220-6. PMID: 7594533.
      View in: PubMed
    80. Harrison KA, Druey KM, Deguchi Y, Tuscano JM, Kehrl JH. A novel human homeobox gene distantly related to proboscipedia is expressed in lymphoid and pancreatic tissues. J Biol Chem. 1994 Aug 05; 269(31):19968-75. PMID: 7914194.
      View in: PubMed